PMA supplement
BP150318 S027: Aptima HIV-1 Quant Dx assay
FDA PMA supplement · 30-Day Notice · Hologic, Inc.
Key facts
| Original PMA | BP150318 |
|---|---|
| Supplement number | S027 |
| Supplement type | 30-Day Notice |
| Trade name | Aptima HIV-1 Quant Dx assay |
| Generic name | Human immunodeficiency virus (hiv) viral load monitoring test |
| Applicant | Hologic, Inc. |
| Product code | QUM |
| Received date | Apr 25, 2022 |
| Decision date | May 17, 2022 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: